The research team hypothesised that the brain might be involved for two reasons: the GLP-1 receptors are abundant in the brain, and the brain and the immune system communicate with all organs in the body
This drug class often lowers inflammation, which has been found to minimize joint pain and the effects of Alzheimer's disease
Today @Roche announced positive results from our Phase I clinical trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of #obesity and type 2 #diabetes
Potential Interaction Risks and Safety Considerations The primary safety concern with dual therapy is additive gastrointestinal side effects: both sermorelin and tirzepatide can cause nausea, vomiting, and delayed gastric emptying
Results Disclaimer: Individual results vary based on baseline health status, specific health goals, protocol adherence, and numerous other factors
The most common side effect of Toujeo is low blood sugar (hypoglycemia), which may be serious and life-threatening